Economic Impact of Antimicrobial Resistance
Author Information
Author(s): John E. McGowan, Jr.
Primary Institution: Emory University School of Medicine
Hypothesis
How does antimicrobial-drug resistance economically impact various stakeholders in healthcare?
Conclusion
The economic impact of antimicrobial-drug resistance is significant and requires better measurement methods to fully understand its implications.
Supporting Evidence
- The economic cost of infections caused by antibiotic-resistant bacteria is estimated to be U.S.$4 to $5 million annually.
- Measurement methods for the economic impact of resistance are still in their infancy and leave many questions unanswered.
- Different stakeholders, including physicians, patients, and healthcare businesses, have varying perspectives on the economic impact of antimicrobial resistance.
Takeaway
Antimicrobial resistance costs a lot of money because it makes infections harder to treat, which means more expensive medicines and longer hospital stays.
Methodology
The review examines various perspectives on the economic impact of antimicrobial resistance and assesses available data on economic methods used for evaluation.
Potential Biases
Studies may not adequately account for different perspectives, leading to potential biases in economic assessments.
Limitations
Current studies are often small and lack uniformity, making it difficult to generalize findings.
Want to read the original?
Access the complete publication on the publisher's website